DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
ABT logo

Abbott Laboratories Stock Price

NYSE:ABT Community·US$182.1b Market Cap
  • 2 Narratives written by author
  • 1 Comments on narratives written by author
  • 372 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

ABT Share Price Performance

US$103.36
-29.29 (-22.08%)
​
US$119.13
Fair Value
US$103.36
-29.29 (-22.08%)
13.2% undervalued intrinsic discount
US$119.13
Fair Value
Price US$103.36
AnalystConsensusTarget US$119.13
NateF US$113.88
Thu, 23 Jul 26
Fair ValueUS$119.13
Share Pricen/a

ABT Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$119.13 13.2% undervalued intrinsic discount

ABT: Legal Wins And Device Momentum Will Support Durable Growth Ahead

4users have liked this narrative
1users have commented on this narrative
177users have followed this narrative
NA
NateF's
Fair Value
·
Fair Value US$113.88 9.2% undervalued intrinsic discount

ABT Market Outlook

2users have liked this narrative
0users have commented on this narrative
26users have followed this narrative
ABT logo
Abbott Laboratories
9.2% undervalued intrinsic discount

ABT Market Outlook

View narrative
NA
NateF
Published 4 Jan 2025
Read Narrative
ABT logo
Abbott Laboratories
13.2% undervalued intrinsic discount

ABT: Legal Wins And Device Momentum Will Support Durable Growth Ahead

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 23 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

NA
ABT logo

ABT Market Outlook

Fair Value: US$113.88 9.2% undervalued intrinsic discount
26 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
ABT logo

ABT: Cancer Diagnostics Expansion And Dividend Streak Will Drive Future Repricing

Fair Value: US$119.13 13.2% undervalued intrinsic discount
177 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Established dividend payer and fair value.

2 Risks
3 Rewards
View Full Analysis

Abbott Laboratories Key Details

US$46.6b

Revenue

US$20.1b

Cost of Revenue

US$26.5b

Gross Profit

US$21.1b

Other Expenses

US$5.4b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
3.12
56.85%
11.59%
63.2%
View Full Analysis

About ABT

Founded
1888
Employees
115000
CEO
Robert Ford
WebsiteView website
www.abbott.com

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Recent ABT News & Updates

Recent updates

No updates

Abbott Laboratories Competitors

UNH logo

UnitedHealth Group

Symbol: NYSE:UNH
Market cap: US$352.8b
ISRG logo

Intuitive Surgical

Symbol: NasdaqGS:ISRG
Market cap: US$124.8b
CVS logo

CVS Health

Symbol: NYSE:CVS
Market cap: US$122.0b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide